Your search for Warfarin returned 94 results

Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.

Findings may help with decision-making in this high-risk patient population.

Study findings revealed an increased risk of surgical intervention in women exposed to rivaroxaban.

The patients, a 71-year-old male and a 62 year-old-male, both on long-term warfarin therapy, presented to the emergency department with symptoms of COVID-19.

The patient developed a generalized maculopapular rash approximately 3 hours after receiving warfarin.

Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.

A recent review published in The Journal of Clinical Pharmacology summarizes the current literature evaluating the potential risks associated with concomitant use of cannabis and antiplatelet agents or anticoagulants.

To shed light on this complex subject, MPR interviewed Joshua D Brown, PharmD, PhD, Assistant Professor, Pharmaceutical Outcomes & Policy.

The patient in this case had been well-controlled on warfarin therapy for over 5 years following mitral valve replacement.

Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…